Novartis AG
Research Novartis AG (NVS) on Bullrun: valuation model: 11.6% undervalued, market cap USD 300.70B, P/E 22.5, dividend yield 3.0%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNVS
- ExchangeNYSE
- CountrySwitzerland
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signal11.6% undervalued
- Market capUSD 300.70B
- P/E22.5
- Dividend yield3.0%
- Financial periodQ1 2026
- RevenueUSD 13.52B
- Net incomeUSD 3.16B
- Free cash flowUSD 2.87B
- Gross margin74.4%
Valuation Snapshot
Bullrun's latest valuation model marks Novartis AG as 11.6% undervalued; latest market cap is USD 300.70B; P/E is 22.5; dividend yield is 3.0%.
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6);
Frequently asked questions
Is Novartis AG overvalued or undervalued?
Bullrun's valuation model currently marks Novartis AG as 11.6% undervalued.
What is Novartis AG's market cap?
Novartis AG's market capitalization is USD 300.70B.
What is Novartis AG's P/E ratio?
Novartis AG's price-to-earnings (P/E) ratio is 22.5.
Does Novartis AG pay a dividend?
Novartis AG has a dividend yield of 3.0%.
What does Novartis AG do?
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF);